Laboratory Guidelines for the Practical Use of HIV Drug Resistance Tests in Patient Follow-Up
- 1 January 2001
- journal article
- review article
- Published by SAGE Publications in Antiviral Therapy
- Vol. 6 (1), 21-39
- https://doi.org/10.1177/135965350100600103
Abstract
HIV drug resistance is one of the major limitations in the successful treatment of HIV-infected patients using currently available antiretroviral combination therapies. When appropriate, drug susceptibility profiles should be taken into consideration in the choice of a specific combination therapy. Guidelines recommending resistance testing in certain circumstances have been issued. Many clinicians have access to resistance testing and will increasingly use these results in their treatment decisions. In this document, we comment on the different methods available, and the relevant issues relating to the clinical application of these tests. Specifically, the following recommendations can be made: (i) genotypic and phenotypic HIV-1 drug resistance analyses can yield complementary information for the clinician. However, insufficient information currently exists as to which approach is preferable in any particular clinical setting; (ii) when HIV-1 drug resistance testing is required, it is recommended that testing be performed on plasma samples obtained before starting, stopping or changing therapy, on samples that have a viral load above the detection limit of the resistance test; (iii) the panel recommends that genotypic and phenotypic HIV-1 drug resistance testing for clinical purposes be performed in a certified laboratory under strict quality control and quality assurance standards; and (iv) the panel recommends that resistance testing laboratories provide clinicians with resistance reports that include a list of drug-related resistance mutations (genotype) and/or a list of drug-related fold resistance values (phenotype), with interpretations of each by an experienced virologist. The interpretation of genotypic and phenotypic analysis is a complex and developing science, and in order to understand HIV-1 drug resistance reports, communication between the requesting clinician and the expert that interpreted the resistance report is recommended.Keywords
This publication has 87 references indexed in Scilit:
- European guidelines on resistance testing: why are they needed?HIV Medicine, 2000
- Sequence Clusters in Human Immunodeficiency Virus Type 1 Reverse Transcriptase Are Associated with Subsequent Virological Response to Antiretroviral TherapyThe Journal of Infectious Diseases, 1999
- Analysis of amino insertion mutations in the fingers subdomain of HIV-1 reverse transcriptase 1 1Edited by J. KarnJournal of Molecular Biology, 1999
- Sequence and Drug Susceptibility of Subtype C Protease from Human Immunodeficiency Virus Type 1 Seroconverters in ZimbabweAIDS Research and Human Retroviruses, 1999
- Managing Resistance to Anti-HIV DrugsDrugs, 1999
- StavudineDrugs, 1996
- Enzymatic Characterization of Human Immunodeficiency Virus Type 1 Reverse Transcriptase Resistant to Multiple 2′,3′-Dideoxynucleoside 5′-TriphosphatesJournal of Biological Chemistry, 1995
- The Appearance of Drug Resistance-Associated Point Mutations in HIV Type 1 Plasma RNA Precedes Their Appearance in Proviral DNAAIDS Research and Human Retroviruses, 1995
- 2′,3′-Dideoxycytidine induced drug resistance in human cellsLife Sciences, 1995
- Comparison of the Sensitivities of Primary Isolates of HIV Type 2 and HIV Type 1 to Antiviral Drugs and Drug CombinationsAIDS Research and Human Retroviruses, 1994